|
|
|
| Competitive Outlook on Lung Cancer Drug Development |
|
| Table of Contents Published: 2009/08 |
| This report includes defined and up to date development strategies for 283 lung cancer therapeutic drugs (>317 projects) within the portfolio of 167 investigators, from Ceased to Marketed. In total the report assesses three different sub-indications of lu ... |
| Target Atlas in Oncology Drug Development: Major Tumor Types |
|
| Published: 2009/03 |
| With the emergence of new technologies and an increased understanding of the biological basis for cancer evolution, the molecular changes that distinguish malignant-cells from normal cells are becoming increasingly apparent, offering a growing range of po ... |
| Triple Target Atlas in Oncology Drug Development |
|
| Published: 2009/03 |
| With the emergence of new technologies and an increased understanding of the biological basis for cancer evolution, the molecular changes that distinguish malignant-cells from normal cells are becoming increasingly apparent, offering a growing range of po ... |
| Analytical Tool - Angiogenesis in Oncology |
|
| Published: 2009/01 |
| Analytical Tool - Angiogenesis in Oncology&%rdquo; offers a unique tool for analyzing the vast amount of strategic possibilities that have emerged in anti-angiogenic drug development for the treatment of cancer. It is at the same time a map of the researc ... |
| Analytical Tool - Apoptosis in Oncology |
|
| Published: 2009/01 |
| Analytical Tool - Apoptosis in Oncology offers a unique tool for analyzing the vast amount of strategic possibilities that have emerged in apoptopic drug development for the treatment of cancer. It is at the same time a map of the research and development ... |
| Analytical Tool - Breast Cancer |
|
| Published: 2009/01 |
| Analytical Tool - Breast Cancer offers a unique tool for analyzing the vast amount of strategic possibilities that have emerged in breast cancer R&D and business development. It is at the same time a map of the research and development, a history of the a ... |
| Analytical Tool - Cancer Vaccines |
|
| Published: 2009/01 |
| Analytical Tool - Cancer Vaccines offers a unique tool for analyzing the vast amount of strategic possibilities that have emerged in cancer vaccine drug development. It is at the same time a map of the research and development, a history of the achievemen ... |
| Analytical Tool - Colorectal Cancer |
|
| Published: 2009/01 |
| Analytical Tool - Colorectal Cancer offers a unique tool for analyzing the vast amount of strategic possibilities that have emerged in colorectal cancer R&D and business development. It is at the same time a map of the research and development, a history ... |
| Analytical Tool - Melanoma |
|
| Published: 2009/01 |
| Analytical Tool - Melanoma offers a unique tool for analyzing the vast amount of strategic possibilities that have emerged in melanoma R&D and business development. It is at the same time a map of the research and development, a history of the achievement ... |
| Analytical Tool - Prostate Cancer |
|
| Published: 2009/01 |
| Analytical Tool - Prostate Cancer offers a unique tool for analyzing the vast amount of strategic possibilities that have emerged in prostate cancer R&D and business development. It is at the same time a map of the research and development, a history of t ... |
| Angiogenesis in Oncology: Drug Pipeline Update 2009 |
|
| Table of Contents Published: 2009/01 |
| There are today at least 250 anti-angiogenic/vascular disruptive/vascular targeting agents drugs in active development for the treatment of various cancers, from early preclinical to marketed drugs. In addition, the accumulated number of ceased drugs over ... |
| Antibodies in Oncology: Drug Pipeline Update 2009 |
|
| Table of Contents Published: 2009/01 |
| The commercial and therapeutic success of antibodies like Rituxan, Avastin, and Erbitux will force the industry to look into the next generation of therapeutic antibodies, preparing themselves for the second wave in the lucrative field of therapeutic anti ... |
| Bladder Cancer Drug Pipeline Update 2009 |
|
| Table of Contents Published: 2009/01 |
| According to the American Cancer Society, bladder cancer is the 6th most common cancer in the U.S. Bladder cancer occurs among both men and women. When found and treated early, the 5 year survival rate is 94%. ... |
| Brain Cancer Drug Pipeline Update 2009 |
|
| Table of Contents Published: 2009/01 |
| Despite the heavy investment made into brain cancer research, primary brain cancer, with glioblastoma multiforme being the most aggressive and most common form, remains one of the most deadly diseases in the developed world. While primary brain tumors are ... |
| Breast Cancer Drug Pipeline Update 2009 |
|
| Table of Contents Published: 2009/01 |
| Breast cancer is the leading cause of cancer-related mortality among women worldwide. High unmet needs still persist for this tumor type. Despite recent drug approvals in the adjuvant and metastatic setting, the overall survival remains below five years. ... |
| Cancer Vaccines: Drug Pipeline Update 2009 |
|
| Table of Contents Published: 2009/01 |
| Cancer vaccines offer an attractive therapeutic addition, delivering treatment of high specificity, low toxicity and prolonged activity. However, despite years of R&D, a reproducible survival benefit has proved elusive, leaving the market wide open. ... |
| Colorectal Cancer Drug Pipeline Update 2009 |
|
| Table of Contents Published: 2009/01 |
| Until a decade ago, 5FU/leucovorin formed the mainstay of colorectal cancer treatment but Camptosar and Eloxatin quickly established themselves as components of gold-standard therapy. The advent of Avastin and Erbitux heralded a new era in the disease man ... |
| Hematological Cancers Drug Pipeline Update 2009 |
|
| Table of Contents Published: 2009/01 |
| Unmet needs across the hematological malignancies remain high, with most traditional therapies conferring low levels of specificity and high toxicity. There are today more than 360 therapeutics targeting hematological cancers in active development, from e ... |
| Immunotherapy in Oncology: Drug Pipeline Update 2009 |
|
| Table of Contents Published: 2009/01 |
| Cancer immunotherapy offers an attractive therapeutic addition, delivering treatment of high specificity, low toxicity and prolonged activity. In this Drug Pipeline Update BioSeeker brings together the fields of antibodies, vaccines, and immunostimulators ... |
| Leukemia Drug Pipeline Update 2009 |
|
| Table of Contents Published: 2009/01 |
| Leukemia includes a broad variety of histological separate disorders which make the leukemia market segmented. There are today more than 240 therapeutics targeting leukemia in active development, from early preclinical to marketed drugs. In addition, the ... |
| Liver Cancer Drug Pipeline Update 2009 |
|
| Table of Contents Published: 2009/01 |
| There are today at least 107 therapeutics targeting liver cancer in active development, from early preclinical to marketed drugs. In addition, the accumulated number of ceased drugs over the last three years amount to another 34 drugs. Liver Cancer Drug P ... |
| Lung Cancer Drug Pipeline Update 2009 |
|
| Table of Contents Published: 2009/01 |
| Non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) comprises over 95% of all lung cancers. High unmet needs still persist for this tumor type and despite two decades of extensive R&D and chemotherapy use, the median overall survival of N ... |
| Lymphoma Drug Pipeline Update 2009 |
|
| Table of Contents Published: 2009/01 |
| Lymphoma is a broad term encompassing a variety of cancers of the lymphatic system. There are today more than 200 therapeutics targeting lymphoma in active development, from early preclinical to marketed drugs. In addition, the accumulated number of cease ... |
| Melanoma Drug Pipeline Update 2009 |
|
| Table of Contents Published: 2009/01 |
| Melanoma comprises just 5% of all skin cancers but it is the most deadly. High unmet needs still persist for this tumor type and despite three decades of extensive R&D, five-year survival of advanced patients remains below 20%. ... |
| Ovarian Cancer Drug Pipeline Update 2009 |
|
| Table of Contents Published: 2009/01 |
| With nearly 60,000 cases of ovarian cancer being diagnosed in the seven major markets each year, this cancer type is by no means small and therefore it remains an important secondary indication for existing and pipeline drugs. ... |
| Pancreatic Cancer Drug Pipeline Update 2009 |
|
| Table of Contents Published: 2009/01 |
| There are today at least 190 therapeutics targeting pancreatic cancer in active development, from early preclinical to marketed drugs. In addition, the accumulated number of ceased drugs over the last three years amount to another 53 drugs. Pancreatic Can ... |
| Prostate Cancer: Drug Pipeline Update 2009 |
|
| Table of Contents Published: 2009/01 |
| Cancer of the prostate is the second most frequently diagnosed cancer in men in the US. The prostate cancer market is reaching maturity, and major players` sales have been eroded by the launch of various LHRH agonist depot formulations. Safety concerns wi ... |
| Renal Cancer Drug Pipeline Update 2009 |
|
| Table of Contents Published: 2009/01 |
| The high existing unmet need in the treatment of renal cancer is reflected by the poor prognosis of patients with advanced stage disease, five- year survival rates with existing cytokine therapy being less than 20% (RCC) in this patient cohort.The identif ... |
| Currently Druggable in Colorectal Cancer |
|
| Table of Contents Published: 2008/12 |
| This report aims to analyze the current and future potential of colorectal cancer pipeline by examining key fundamentals across the entire pipeline of drug candidates. BioSeeker has identified three fundamental dimensions to outline the competitive landsc ... |
| Cancer Vaccines: Aim and Shoot |
|
| Table of Contents Published: 2008/05 |
| This report aims to analyze the current and future potential of cancer vaccines by examining key fundamentals across the entire pipeline of cancer vaccine drug candidates. BioSeeker has identified three fundamental dimensions to outline the competitive la ... |
| Melanoma Drug Pipeline Update 2008 |
|
| Published: 2008/04 |
| Melanoma comprises just 5% of all skin cancers but it is the most deadly. High unmet needs still persist for this tumor type and despite three decades of extensive R&D, five-year survival of advanced patients remains below 20%. ... |
| Renal Cancer Drug Pipeline Update 2008 |
|
| Published: 2008/04 |
| The high existing unmet need in the treatment of renal cancer is reflected by the poor prognosis of patients with advanced stage disease, five- year survival rates with existing cytokine therapy being less than 20% (RCC) in this patient cohort. ... |
| The Drug Target Atlas of Apoptopic Drugs in Oncology |
|
| Table of Contents Published: 2008/02 |
| In the report, BioSeeker reports on 90 unique drug target combinations, each comprised of a different collection or mix of individually defined targets, for 114 apoptopic drugs designed for the treatment of 48 different cancer indications. The highest deg ... |
| Decoding Big Pharmas R&D Strategy in Oncology |
|
| Table of Contents Published: 2007/09 |
| This report, Decoding Big Pharma' s R&D Strategy in Oncology, is based on five major pharmaceutical companies in the oncology arena: Bristol-Myers Squibb, GlaxoSmithKline, Hoffmann-La Roche, and Sanofi-Aventis. Between them and together with their respect ... |
| Analytical Tool - Leukemia Therapeutics & Competitive Insights |
|
| Published: 2007/05 |
| Analytical Tool - Leukemia Therapeutics & Competitive Insights offers a unique tool for analyzing the vast amount of strategic possibilities that have emerged in leukemia R&D and business development. It is at the same time a map of the research and devel ... |
| Global Cancer Focus Company Directory |
|
| Table of Contents Published: 2007/04 |
| Global Cancer Focus Company Directory pulls out virtually all cancer drug developing companies in the world. After several acquisitions and mergers in the market place, BioSeeker offers you the tool to get an updated look on the competitive landscape in o ... |
| Targeted Therapeutics in Non-Small Cell Lung Cancer |
|
| Table of Contents Published: 2007/04 |
| Lung cancer is the third most common malignant disease and the first leading cause of cancer death in the western world. Yet platinum agent constitutes the current mainstay of front-line metastatic lung cancer treatment. There are currently two platinum-b ... |
| Competitive Outlook on Apoptosis in Oncology |
|
| Table of Contents Published: 2006/12 |
| Cancer cells frequently and possibly invariably possess apoptotic defects. In this context, apoptotic pathways provide exciting molecular targets for new therapeutic agents to specifically promote apoptosis of cancer cells ... |
| Current and Future Therapies for Lung Cancer |
|
| Table of Contents Published: 2006/03 |
| Lung cancer is the third most common malignant disease and the first leading cause of cancer death in the western world. Yet platinum agent constitutes the current mainstay of front-line metastatic lung cancer treatment. ... |
| Current and Future Therapies for Colorectal Cancer |
|
| Table of Contents Published: 2005/09 |
| Colorectal cancer has become an excellent tumor model for evaluating new therapeutic strategies. Development of a detailed understanding of how this cancer develops, spreads, and grows allows a tailored approach to all stages of treatment: prevention, adj ... |
| Cancer Vaccines Fantasy or Future? |
|
| Table of Contents Published: 2005/02 |
| The new and updated progress analysis report Cancer Vaccines Fantasy or Future by BioSeeker Group continues to provide the latest information and analysis on industry related as well as important academic activities. ... |
| Large Pharma: 2004 a year of progress |
|
| Table of Contents Published: 2004/12 |
| The gross majority of all drugs, which reach late stage of development, are someway or another passed on to the large pharmaceutical companies because they hold the capital needed to conduct the expensive clinical trials as well as the regulatory commitme ... |
|
 Top
|
|
View Cart
